Skip to content

KRMN KRMN Net proceeds from sales of subsidiary shares

Net proceeds from sales of subsidiary shares at other companies

Ingram Micro logo
Ingram MicroINGM
$0-100%
Karman Holdings Inc. logo
Karman Holdings Inc.KRMN
$1.03M
Intel logo
IntelINTC
$230.25M
Rhythm Pharmaceuticals, Inc. logo
Rhythm Pharmaceuticals, Inc.RYTM
$47.16M
Medtronic logo
MedtronicMDT
$134.5M
CoreWeave, Inc.
 logo
CoreWeave, Inc. CRWV
$0-100%

Other financials

Income statement

See full
Revenue$151.2M+51.0%
Gross profit$63.9M+61.9%
Operating income$21.5M+115%
Net income$7.8M+262%
EPS (diluted)$0.06+250%

Balance sheet

See full
Cash & equivalents$73.8M-35.1%
Total debt$861.4M+109%
Total equity$405.7M+16.3%
Total assets$1.4B+62.0%

Cash flow

See full
Operating cash flow$209.0K+102%
CapEx$7.4M+46.3%
Free cash flow-$7.2M+61.5%

Valuation

See full
Market cap$6.68B
Enterprise value$7.46B
P/E222.8×
P/S12.8×

Profitability

See full
Gross margin41%+1.7pp
Operating margin16.2%-0.4pp
Net margin5.7%+4.1pp
FCF margin-6.7%-15.1pp

Returns & leverage

See full
Return on equity7.9%+5.8pp
Debt / equity2.1×+0.9×
Current ratio3.5×+0.2×

Where this comes from

Reported directly by KRMN in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceInitialPublicOffering.

The official record: KRMN’s 10-K, filed April 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about KRMN's net proceeds from sales of subsidiary shares.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is KRMN's net proceeds from sales of subsidiary shares?
KRMN (KRMN) reported net proceeds from sales of subsidiary shares of $1.03M in Q4 2025.
What does net proceeds from sales of subsidiary shares mean?
Represents the total cash proceeds received from the initial sale of equity shares to the public market. This metric highlights the primary capital infusion used to fund growth initiatives, debt reduction, or general corporate purposes.